Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies

Hamza Boucetta, Lei Zhang, Alejandro Sosnik, Wei He

Research output: Contribution to journalReview articlepeer-review


Pulmonary arterial hypertension (PAH) is a rare, serious, and incurable disease characterized by high lung pressure. PAH-approved drugs based on conventional pathways are still not exhibiting favorable therapeutic outcomes. Drawbacks like short half-lives, toxicity, and teratogenicity hamper effectiveness, clinical conventionality, and long-term safety. Hence, approaches like repurposing drugs targeting various and new pharmacological cascades and/or loaded in non-toxic/efficient nanocarrier systems are being investigated lately. This review summarizes the status of conventional, repurposed, either in vitro, in vivo, and/or in clinical trials of PAH treatment. In-depth description, discussion, and classification of the new pharmacological targets and nanomedicine strategies with a description of all the nanocarriers that showed promising efficiency in delivering drugs are discussed. Ultimately, an illustration of the different nucleic acids tailored and nanoencapsulated within different types of nanocarriers to restore the pathways affected by this disease is presented.

Original languageEnglish
Pages (from-to)236-258
Number of pages23
JournalJournal of Controlled Release
StatePublished - Jan 2024


  • Gene therapy
  • Nanocarriers
  • Nanomedicines
  • New pharmacological targets
  • Pulmonary arterial hypertension
  • Repurposing drugs

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science


Dive into the research topics of 'Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies'. Together they form a unique fingerprint.

Cite this